Dimensional Fund Advisors LP Makes New $111,000 Investment in Protara Therapeutics, Inc. (NASDAQ:TARA)

Dimensional Fund Advisors LP acquired a new stake in shares of Protara Therapeutics, Inc. (NASDAQ:TARA) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 20,997 shares of the company’s stock, valued at approximately $111,000. Dimensional Fund Advisors LP owned about 0.10% of Protara Therapeutics at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Walleye Capital LLC acquired a new position in shares of Protara Therapeutics during the 4th quarter worth about $1,166,000. Barclays PLC purchased a new position in shares of Protara Therapeutics during the 4th quarter worth approximately $492,000. ADAR1 Capital Management LLC purchased a new position in shares of Protara Therapeutics during the 4th quarter worth approximately $648,000. Geode Capital Management LLC boosted its position in shares of Protara Therapeutics by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 179,593 shares of the company’s stock worth $948,000 after purchasing an additional 9,553 shares during the period. Finally, Commonwealth Equity Services LLC lifted its holdings in Protara Therapeutics by 90.4% during the 4th quarter. Commonwealth Equity Services LLC now owns 37,000 shares of the company’s stock worth $195,000 after buying an additional 17,572 shares in the last quarter. 38.13% of the stock is owned by hedge funds and other institutional investors.

Protara Therapeutics Stock Up 2.6%

TARA stock opened at $3.19 on Friday. Protara Therapeutics, Inc. has a fifty-two week low of $1.60 and a fifty-two week high of $10.48. The firm’s 50-day simple moving average is $3.93 and its 200 day simple moving average is $4.13. The stock has a market cap of $123.08 million, a PE ratio of -1.13 and a beta of 1.73.

Protara Therapeutics (NASDAQ:TARA) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.18. Equities analysts forecast that Protara Therapeutics, Inc. will post -3.32 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Jacqueline Zummo sold 21,224 shares of the business’s stock in a transaction on Wednesday, March 26th. The shares were sold at an average price of $4.53, for a total transaction of $96,144.72. Following the transaction, the insider now owns 98,861 shares of the company’s stock, valued at approximately $447,840.33. The trade was a 17.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 12.50% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on TARA. Lifesci Capital assumed coverage on shares of Protara Therapeutics in a report on Tuesday, March 11th. They issued an “outperform” rating and a $22.00 price objective on the stock. Scotiabank initiated coverage on shares of Protara Therapeutics in a research report on Wednesday, April 16th. They set a “sector outperform” rating and a $12.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 target price on shares of Protara Therapeutics in a report on Monday, April 28th. Finally, Cantor Fitzgerald began coverage on shares of Protara Therapeutics in a report on Friday, March 14th. They set an “overweight” rating on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $20.40.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.